newsLast patient visit in Phase IIa study with RHB-104 for multiple sclerosis3 August 2016 | By RedHill Biopharma Ltd.The last patient visit has been completed in the Phase IIa study evaluating RHB-104 in patients treated for relapsing-remitting multiple sclerosis (RRMS)...
newsRedHill Biopharma has positive results with RHB-104 for multiple sclerosis1 August 2016 | By RedHill Biopharma Ltd.RHB-104 for relapsing-remitting multiple sclerosis show positive safety and efficacy signals after the 24-week treatment period ...
newsEncouraging top-line interim results for RHB-104 in RRMS5 April 2016 | By Victoria WhiteRedHill has announced encouraging top-line interim results from its CEASE-MS study of RHB-104 in patients with relapsing-remitting multiple sclerosis...